Bristol Myers Squibb (CELG-RI) Equity Ratio (2009 - 2026)

Bristol Myers Squibb has disclosed Equity Ratio across 18 years of filings, most recently posting 0.23 for Q1 2026.

• In Q1 2026, Equity Ratio rose 7245.55% year-over-year to 0.23; the TTM figure through Mar 2026 stood at 0.23 (up 7245.55% YoY), while the FY2025 annual figure was 0.21, up 27.41% from the prior year.
• Equity Ratio climbed to 0.23 in Q1 2026, from 0.21 in the prior quarter.
• Over the last five years, Equity Ratio for CELG-RI reached as high as 0.31 in Q3 2023 and fell as low as 0.44 in Q1 2024.
• The 5-year median for Equity Ratio is 0.0 (2024), against an average of 0.01.
• Annual changes were most pronounced in 2024 — Equity Ratio tumbled 14346.95% — and 2026, when it soared 7245.55%.
• A 5-year view of Equity Ratio shows it stood at 0.01 in 2022, then decreased by 22.79% to 0.02 in 2023, then jumped by 1091.18% to 0.16 in 2024, then grew by 27.41% to 0.21 in 2025, then advanced by 13.11% to 0.23 in 2026.
• According to Business Quant data, Equity Ratio over the past three periods registered 0.23, 0.21, and 0.19 for Q1 2026, Q4 2025, and Q3 2025 respectively.